Just caught up on Keros' latest financials and honestly, the turnaround story here is pretty compelling. We're talking about a company that went from a $187M net loss in 2024 to posting $87M in net income for 2025. That's a massive swing, and it's almost entirely due to their Takeda partnership deal which brought in $244M in revenue.

What makes this interesting beyond just the numbers is where Keros is actually heading with their pipeline. They've got two main shots on goal here - Rinvatercept for neuromuscular diseases like DMD and ALS, and Elritercept for blood-related issues in MDS and myelofibrosis patients. The Phase 1 data on Rinvatercept looked clean enough that they're moving forward with Phase 2 trials, which should be kicking off pretty soon if they haven't already.

The Takeda deal basically de-risked Keros' burn rate significantly. They ended the year with $287M in cash, which should keep them funded well into 2028. That's solid runway for a biotech at this stage. They're also making moves on the leadership side - new board member coming in, promoted their Chief Legal Officer. Standard corporate housekeeping but signals stability.

From a market perspective, Keros stock has been trading between $9 and $22 over the past year, so there's been some volatility. The company's basically positioned itself as a play on muscle and blood disorder therapeutics, which are both decent-sized markets if they can get approvals. The licensing revenue model also gives them more flexibility than pure-play biotech companies burning cash on R&D.

Worth keeping on the radar if you're into biotech exposure. The pipeline timelines are getting real now, and we should see some meaningful data points emerge over the next 12-18 months.